LGND
Ligand Pharmaceuticals Incorporated
Healthcare · Biotechnology · NGM
$237.00
Data: 2026-05-28
✓ ETHICAL PASS

Unknown MOAT
HIGH
Data Confidence: 100.0%
Key Metrics

How this company measures up on the fundamentals that matter

Market Cap
$4.7B
Total market value of the company
Trailing P/E
30.80
Premium valuation
Forward P/E
20.77
Based on estimated future earnings — lower means cheaper
Rev Growth
+14.1%
Year-over-year revenue change
Profit Margin
55.9%
How much profit the company keeps from each dollar of revenue
ROE
17.1%
Return on equity — how efficiently it uses shareholder money
Analyst Target
$272.50
+15% from current price — median analyst estimate
Recommendation
STRONG_BUY
Consensus view from 10 analysts covering this stock
About Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.

https://www.ligand.com

Country: United States Employees: 47 Industry: Biotechnology
Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
0.0% N/A
Debt must be below 33% of total assets
Cash Ratio
0.0% N/A
Interest-bearing cash below 33% of assets
Receivables
0.0% N/A
Receivables below 49% of assets
Revenue Purity
0.0% PASS
Non-compliant revenue below 5% — any excess requires purification
Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime
MARKUP
Price trending up with increasing momentum
Sharpe Ratio
1.517
Excellent risk-adjusted returns
Kelly Fraction
0.1235
Suggested allocation is meaningful — the edge justifies a position
Calmar Ratio
2.608
Returns exceed worst-case losses — strong risk profile
Annual Return
66.7%
Historical annualised return based on price data
Max Drawdown
-25.6%
Largest peak-to-trough decline — the worst it has been
HMM State
SIDEWAYS
Price consolidating — no clear directional bias
Days in State
1
How long the current regime has persisted — longer means more stable
Market Data

Trading characteristics and market positioning

Beta
1.07
Moves slightly more than the broader market
52W High
$247.38
4% below the year high
52W Low
$98.89
140% above the year low
Avg Volume
231,621
Average daily shares traded — higher means easier to buy and sell
Short Ratio
7.2
Days it would take all short sellers to cover — higher means more crowded
Short % Float
9.0%
Moderate short interest
Div Yield
N/A
Annual dividend as a percentage of the share price
EPS (TTM)
$7.66
Earnings per share over the last 12 months
Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity
45.32
Heavy leverage — higher financial risk if revenues decline
Current Ratio
21.28
Strong balance sheet — comfortably covers short-term obligations
Quick Ratio
20.81
Like current ratio but excludes inventory — stricter test
Gross Margin
83.2%
Revenue left after cost of goods — higher means pricing power
Operating Margin
33.6%
Profit from core operations before interest and tax
Free Cash Flow
$142M
Positive — the business generates more cash than it spends
Revenue (TTM)
$274M
Total revenue over the last 12 months
Net Income
$154M
Profitable — the bottom line is positive
Analyst Coverage
Analysts
10
Target High
$330.00
Target Median
$272.50
Target Low
$220.00
Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Discover More
Alpha Insights Market Intelligence Titan Watch Ethical Screener Insider Intelligence Track Record Ethical Finance Zakat Calculator Iran Oil Tracker Foundry (292 articles) Indicators Join Free →

Get our weekly market brief free.